menu
    • menu

    Company profile for Anthos Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascu...
    Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Anthos TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    101 Main Street Cambridge MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://anthostherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anthos-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Blackstone & Anthos Announce Novartis has Completed Acquisition
    Blackstone & Anthos Announce Novartis has Completed Acquisition

    03 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250403148958/en/Blackstone-Life-Sciences-and-Anthos-Therapeutics-Announce-Novartis-has-Completed-the-Acquisition-of-Anthos-Therapeutics-in-a-Deal-Valued-at-up-to-%243.1B-with-%24925M-Paid-Upfront

    BUSINESSWIRE
    03 Apr 2025
    Share Share
    Anthos Therapeutics Shares New Data from AZALEA-TIMI 71 Study
    Anthos Therapeutics Shares New Data from AZALEA-TIMI 71 Study

    29 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/29/3051766/0/en/Anthos-Therapeutics-Shares-New-Data-from-the-Landmark-AZALEA-TIMI-71-Study-Demonstrating-the-Factor-XI-Inhibitor-Abelacimab-Significantly-Reduced-Bleeding-in-Patients-Regardless-of.html

    GLOBENEWSWIRE
    29 Mar 2025
    Share Share
    Novartis buys Blackstone's Anthos for up to $3.1 billion
    Novartis buys Blackstone's Anthos for up to $3.1 billion

    12 Feb 2025

    // REUTERS

    https://www.reuters.com/markets/deals/novartis-agrees-acquire-anthos-up-31-bln-2025-02-11/

    REUTERS
    12 Feb 2025
    Share Share
    Novartis Buys Anthos For $925M To Boost Cardiovascular Pipeline
    Novartis Buys Anthos For $925M To Boost Cardiovascular Pipeline

    11 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/11/3023892/0/en/Novartis-bolsters-late-stage-cardiovascular-pipeline-with-agreement-to-acquire-Anthos-Therapeutics-for-USD-925-million-upfront.html

    GLOBENEWSWIRE
    11 Feb 2025
    Share Share
    Abelacimab Cuts Bleeding By 62% Vs Xarelto In Atrial Fibrillation
    Abelacimab Cuts Bleeding By 62% Vs Xarelto In Atrial Fibrillation

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013921/0/en/Data-Published-Today-in-the-New-England-Journal-of-Medicine-Demonstrates-Anthos-Therapeutics-novel-Factor-XI-inhibitor-Abelacimab-150mg-Reduced-Major-or-Clinically-Relevant-Non-Maj.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share
    Anthos Therapeutics Shares New AZALEA-TIMI 71 Study Analysis
    Anthos Therapeutics Shares New AZALEA-TIMI 71 Study Analysis

    16 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/16/2982367/0/en/Anthos-Therapeutics-Shares-New-Analysis-from-the-Landmark-AZALEA-TIMI-71-Study-Demonstrating-the-Factor-XI-Inhibitor-Abelacimab-Substantially-Reduced-Bleeding-in-Patients-on-Antipl.html

    GLOBENEWSWIRE
    16 Nov 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search